Pulmatrix Inc. Scores Licensing Agreement with Johnson & Johnson

Clinical stage biopharmaceutical company Pulmatrix has announced a licensing agreement with Johnson & Johnson this week.
The Massachusetts-based company entered a licensing and development agreement with the Lung Cancer Initiative at J&J, providing the latter an option to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception.

Pulmatrix, which is engaged in the development of inhaled therapies to treat serious pulmonary diseases, said its iSPERSE platform has the ability to enhance the safety and efficacy profile of promising drug candidates.

“We applied the iSPERSE technology to RV1162/PUR1800, the lead in-licensed inhibitor and helped unlock its clinical potential by improving the product’s profile from the original formulation,” Pulmatrix CEO Ted Raad stated.

According to a release, the agreement provides for Pulmatrix receiving a $7.2-million upfront payment and an additional $2-million payment on completion of an ongoing Phase 1b study of RV1162/PUR1800 in stable chronic obstructive pulmonary disease patients.

The company said the study is on track to be completed by year end 2020. This year the company also expects data from
its Phase 2 Pulmazole program and has plans to introduce proprietary, wholly owned iSPERSE-enabled 505(b)(2) assets to its pipeline.

Disclaimer: We have no position in any of the companies mentioned and have not been compensated for this article.